SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish the details of request for issue of duplicate share certificate reported by shareholder of the Company SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 02, 2022 for Raksha Sudhir Valia SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Disclosure Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
SEZABY TM (phenobarbital sodium powder for injection) approved by US FDA for the treatment of neonatal seizures SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Submission Of Certificate From Statutory Auditor In Terms Of Regulation 169(5) Of The Securities And Exchange Board Of India (Issue Of Capital And Disclosure Requirements) Regulations, 2018
Submission of Certificate from Statutory Auditor in terms of Regulation 169(5) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Addendum To Our Communication Dated November 08, 2022 W.R.T. Outcome Of The Meeting Of The Securities Allotment Committee Held On November 08, 2022
We refer to our letter no. SPARC/Sec/SE/2022-23/069 dated November 08, 2022 wherein we had inter alia stated that Shanghvi Finance Private Limited (SFPL) has ceased to be the Company's holding company as its percentage holding has reduced from 50.47% to 49.84%, consequent to allotment of equity shares made on November 08, 2022. The Company (SPARC) is in now receipt of a communication from SFPL stating that SFPL, along with its subsidiaries, still controls more than 50% of the voting power in SPARC; and hence it continues to remain the Holding Company of SPARC. Considering this fact, we would like to mention that SFPL continues to remain the Holding Company of SPARC. SunPharma,SPARC ink pact for injection products to treat neonatal seizure
Mohali plant put under OAI by the US regulator SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
SPARC and Sun Pharma enter into a license agreement for commercialization of phenobarbital for injection in the US SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Allotment Of Equity Shares Upon Conversion Of Warrants And Consequent To Which, Shanghvi Finance Private Limited Has Ceased To Be The Company'S Holding Company As Its Percentage Shareholding In The Company Has Reduced From 50.47% To 49.84%.
allotment of equity shares upon conversion / exchange of equal number of warrants and consequent to the said allotment, Shanghvi Finance Private Limited (SFPL) has ceased to be the Company's Holding Company as its percentage shareholding in the Company has reduced from 50.47% to 49.84%. The number of shares held by SFPL in the Company remain unchanged.